Impact of ITS-Based Sequencing on Antifungal Treatment of Patients with Suspected Invasive Fungal Infections.
ITS-sequencing
antifungal therapy
invasive fungal infections
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
08
02
2020
revised:
14
03
2020
accepted:
25
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Molecular techniques including the sequencing of fungal-specific DNA targets are increasingly used in the diagnosis of suspected invasive fungal infections. In contrast to established biomarkers like galactomannan or 1-3-β-d-glucan, the clinical impact of these methods remains unknown. We retrospectively investigated the impact of ITS1-sequencing on antifungal treatment strategies in 71 patients (81 samples) with suspected invasive fungal infections. ITS-sequencing either confirmed already ongoing antifungal therapy (19/71 patients, 27%), led to a change in antifungal therapy (11/71, 15%) or supported the decision to withhold antifungal treatment (34/71, 48%) (in seven of 71 patients, ITS-sequencing results were obtained postmortem). ITS-sequencing results led to a change in antifungal therapy in a relevant proportion of patients, while it confirmed therapeutic strategies in the majority. Therefore, ITS-sequencing was a useful adjunct to other fungal diagnostic measures in our cohort.
Identifiants
pubmed: 32230706
pii: jof6020043
doi: 10.3390/jof6020043
pmc: PMC7345167
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Med Mycol. 2014 Jul;52(5):455-61
pubmed: 24906361
Nat Methods. 2012 Apr 27;9(5):425-6
pubmed: 22543370
Clin Infect Dis. 2013 May;56(9):1284-92
pubmed: 23315320
J Clin Microbiol. 2016 Jan;54(1):148-52
pubmed: 26560539
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
J Infect. 2012 Dec;65(6):588-91
pubmed: 23078908
J Infect. 2018 Sep;77(3):235-241
pubmed: 29972764
Lancet Infect Dis. 2019 Dec;19(12):e405-e421
pubmed: 31699664
PLoS One. 2016 May 20;11(5):e0155033
pubmed: 27206014
Clin Infect Dis. 2014 Dec 15;59(12):1696-702
pubmed: 25165088
Clin Infect Dis. 2015 Mar 15;60(6):892-9
pubmed: 25586686
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
Lancet Infect Dis. 2003 Nov;3(11):685-702
pubmed: 14592598
Clin Infect Dis. 2019 Dec 05;:
pubmed: 31802125
Clin Infect Dis. 2006 Jul 1;43(1):25-31
pubmed: 16758414
Med Mycol. 2020 Jul 1;58(5):632-638
pubmed: 31613367
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Virulence. 2017 Apr 3;8(3):334-341
pubmed: 27687858
Am J Respir Crit Care Med. 2014 Oct 15;190(8):922-9
pubmed: 25203869
Med Mycol. 2020 Jul 1;58(5):650-660
pubmed: 31758176
Front Microbiol. 2017 Feb 14;8:180
pubmed: 28261162
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
pubmed: 16127033
Nat Rev Microbiol. 2019 Jan;17(2):95-109
pubmed: 30442909
PLoS One. 2011 Mar 09;6(3):e17288
pubmed: 21408061
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Mycoses. 2017 Dec;60(12):818-825
pubmed: 28877383
J Clin Microbiol. 2020 Feb 24;58(3):
pubmed: 31852762
Med Mycol. 2000;38 Suppl 1:147-59
pubmed: 11204140
Front Microbiol. 2018 Sep 19;9:2208
pubmed: 30283425
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
J Fungi (Basel). 2017 Oct 18;3(4):
pubmed: 29371573
Sci Rep. 2018 May 3;8(1):6964
pubmed: 29725065